Takeda Pharmaceutical Company Limited
TKPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $7,426,910,439 | $6,621,265,884 | $6,743,408,852 | $5,601,525,092 |
| - Cash | $385,113,000 | $457,800,000 | $533,530,000 | $849,695,000 |
| + Debt | $4,515,265,000 | $5,463,391,000 | $4,382,341,000 | $4,345,411,000 |
| Enterprise Value | $11,557,062,439 | $11,626,856,884 | $10,592,219,852 | $9,097,241,092 |
| Revenue | $4,581,551,000 | $4,263,762,000 | $4,027,478,000 | $3,569,006,000 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | $3,001,334,000 | $2,832,257,000 | $2,783,406,000 | $2,462,160,000 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| EBITDA | $1,073,791,000 | $900,328,000 | $1,156,463,000 | $1,008,154,000 |
| % Margin | 23.4% | 21.1% | 28.7% | 28.2% |
| Net Income | $107,928,000 | $144,067,000 | $317,017,000 | $230,059,000 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 67.23 | 91.16 | 201.94 | 145.87 |
| % Growth | -26.3% | -54.9% | 38.4% | – |
| Operating Cash Flow | $1,057,182,000 | $716,344,000 | $977,156,000 | $1,123,105,000 |
| Capital Expenditures | -$379,625,000 | -$480,730,000 | -$633,689,000 | -$186,037,000 |
| Free Cash Flow | $677,557,000 | $235,614,000 | $343,467,000 | $937,068,000 |